OncoMatch

OncoMatch/Clinical Trials/NCT06875310

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Is NCT06875310 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for carcinoma, non-small-cell lung.

Phase 3RecruitingMirati Therapeutics Inc.NCT06875310Data as of May 2026

Treatment: Adagrasib · Pembrolizumab · Carboplatin · Pemetrexed · Cisplatin — This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: PD-L1 (CD274) any expression (0 to 100%)

Required: KRAS g12c mutation

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: KRAS inhibitor (sotorasib, adagrasib)

Treatment targeting KRAS G12C mutation (eg, sotorasib, adagrasib) in any setting.

Lab requirements

Blood counts

Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities [excluded]

Liver function

Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities [excluded]

Cardiac function

ECG abnormalities [excluded]; ongoing treatment with concomitant medication known to cause prolonged QTc interval and that cannot be switched to alternative treatment prior to study entry [excluded]

Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities. Ongoing treatment with concomitant medication known to cause prolonged QTc interval and that cannot be switched to alternative treatment prior to study entry.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Local Institution - 0347 · Birmingham, Alabama
  • Local Institution - 0686 · Springdale, Arkansas
  • Local Institution - 0581 · Fullerton, California
  • Local Institution - 0682 · Loma Linda, California
  • Local Institution - 0202 · Long Beach, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify